Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study
Lisa Licitra(University of Milan), Song Qu, J. Li, Nathaniel Bouganim(McGill University Health Centre), Adriana Domingues Valadares, Paul Swiecicki(University of Michigan), Hussein Soudy Hussein, Thiago Bueno de Oliveira(AC Camargo Hospital), Burak Gümüşçü(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tibor Csőszi, Júlia Pastorello, Zhijun Yuan(Zhejiang University), Karine Martins da Trindade, Anna Spreafico(University Health Network), Guoqing Hu(Tongji Hospital), Mu Yang(Taipei Veterans General Hospital), Olivier Dumas, Meiyu Fang(Zhejiang Cancer Hospital), Anne Taylor, Kunyu Yang, Makoto Tahara(National Cancer Center Hospital East), Luciano Viana, Michael Boyer, Juan Shen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ye Guo(Shanghai East Hospital), Gustavo Alves, Ning Jia, Corina Dutcus(Eisai (United States)), Sercan Aksoy(Hacettepe University Hospital), Jérome Fayette(Centre Léon Bérard), Marcio Costa, Mivael Olivera Hurtado de Mendoza(Instituto Nacional de Enfermedades Neoplásicas), Hui Wu, Ye Guo(Shanghai East Hospital), Thiago Oliveira, Ying Cheng, Qingyuan Zhang, Xiangqian Zheng, Liangfang Shen, Nianyong Chen, Shunji Takahashi(The Cancer Institute Hospital), On behalf of the RESOLVE-Lung investigators, Yan Sun, Kimberly Benjamin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert I. Haddad(Dana-Farber Cancer Institute), Caroline Even(Institut Gustave Roussy), Mikhail Klochikhin, Kevin Harrington(Royal Marsden NHS Foundation Trust), Chinyere E. Okpara(Eisai (United Kingdom))
Cited by 0
Related Papers
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k